Challenges in LC-MS-based metabolomics for Alzheimer's disease early detection: targeted approaches versus untargeted approaches.
Alzheimer’s disease
Biomarkers
Targeted metabolomics
Untargeted metabolomics
Journal
Metabolomics : Official journal of the Metabolomic Society
ISSN: 1573-3890
Titre abrégé: Metabolomics
Pays: United States
ID NLM: 101274889
Informations de publication
Date de publication:
28 08 2021
28 08 2021
Historique:
received:
30
01
2021
accepted:
06
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
15
1
2022
Statut:
epublish
Résumé
Alzheimer's disease (AD) is one of the most common causes of dementia in old people. Neuronal deficits such as loss of memory, language and problem-solving are severely compromised in affected patients. The molecular features of AD are Aβ deposits in plaques or in oligomeric structures and neurofibrillary tau tangles in brain. However, the challenge is that Aβ is only one piece of the puzzle, and recent findings continue to support the hypothesis that their presence is not sufficient to predict decline along the AD outcome. In this regard, metabolomic-based techniques are acquiring a growing interest for either the early diagnosis of diseases or the therapy monitoring. Mass spectrometry is one the most common analytical platforms used for detection, quantification, and characterization of metabolic biomarkers. In the past years, both targeted and untargeted strategies have been applied to identify possible interesting compounds. The overall goal of this review is to guide the reader through the most recent studies in which LC-MS-based metabolomics has been proposed as a powerful tool for the identification of new diagnostic biomarkers in AD. To this aim, herein studies spanning the period 2009-2020 have been reported. Advantages and disadvantages of targeted vs untargeted metabolomic approaches have been outlined and critically discussed.
Sections du résumé
BACKGROUND
Alzheimer's disease (AD) is one of the most common causes of dementia in old people. Neuronal deficits such as loss of memory, language and problem-solving are severely compromised in affected patients. The molecular features of AD are Aβ deposits in plaques or in oligomeric structures and neurofibrillary tau tangles in brain. However, the challenge is that Aβ is only one piece of the puzzle, and recent findings continue to support the hypothesis that their presence is not sufficient to predict decline along the AD outcome. In this regard, metabolomic-based techniques are acquiring a growing interest for either the early diagnosis of diseases or the therapy monitoring. Mass spectrometry is one the most common analytical platforms used for detection, quantification, and characterization of metabolic biomarkers. In the past years, both targeted and untargeted strategies have been applied to identify possible interesting compounds.
AIM OF REVIEW
The overall goal of this review is to guide the reader through the most recent studies in which LC-MS-based metabolomics has been proposed as a powerful tool for the identification of new diagnostic biomarkers in AD. To this aim, herein studies spanning the period 2009-2020 have been reported. Advantages and disadvantages of targeted vs untargeted metabolomic approaches have been outlined and critically discussed.
Identifiants
pubmed: 34453619
doi: 10.1007/s11306-021-01828-w
pii: 10.1007/s11306-021-01828-w
pmc: PMC8403122
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
78Informations de copyright
© 2021. The Author(s).
Références
Adv Exp Med Biol. 2017;965:E1-E2
pubmed: 28397194
Anal Chem. 2019 Apr 2;91(7):4396-4404
pubmed: 30831026
PLoS One. 2011;6(7):e21643
pubmed: 21779331
Neurol Res. 2004 Jul;26(5):573-8
pubmed: 15265277
Int J Mol Sci. 2015 Dec 10;16(12):29446-53
pubmed: 26690411
J Lipid Res. 2016 Jan;57(1):36-45
pubmed: 26538545
Nat Med. 2014 Apr;20(4):415-8
pubmed: 24608097
Metabolomics. 2018;14(6):72
pubmed: 29805336
Cell Rep Med. 2020 Nov 17;1(8):100138
pubmed: 33294859
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
PLoS Med. 2018 Jan 25;15(1):e1002482
pubmed: 29370177
Neurobiol Aging. 2014 Feb;35(2):271-8
pubmed: 24041970
Sci Rep. 2020 Sep 24;10(1):15612
pubmed: 32973179
Mass Spectrom Rev. 2013 Jan-Feb;32(1):43-71
pubmed: 22941854
Cell Tissue Bank. 2008 Sep;9(3):181-94
pubmed: 18543077
Analyst. 2016 Nov 14;141(23):6362-6373
pubmed: 27722450
Electrophoresis. 2009 Apr;30(7):1235-9
pubmed: 19288586
Alzheimers Dement. 2019 Jan;15(1):76-92
pubmed: 30337151
Nat Protoc. 2018 Apr;13(4):633-651
pubmed: 29494574
Cells. 2020 Jul 30;9(8):
pubmed: 32751526
J Chromatogr A. 2014 Dec 29;1374:1-13
pubmed: 25444251
Metabolomics. 2007 Sep;3(3):211-221
pubmed: 24039616
Front Bioeng Biotechnol. 2015 Mar 05;3:23
pubmed: 25798438
Metabolomics. 2018;14(1):1
pubmed: 29249916
Bioessays. 2013 Oct;35(10):847-52
pubmed: 23943322
Nat Commun. 2020 Nov 10;11(1):5698
pubmed: 33173055
Neurobiol Aging. 2015 Jan;36(1):68-80
pubmed: 25311278
Sci Rep. 2020 Jun 18;10(1):9884
pubmed: 32555372
Alzheimers Dement (Amst). 2019 Sep 05;11:619-627
pubmed: 31517024
Alzheimers Dement. 2017 Feb;13(2):140-151
pubmed: 27693183
Ann Neurol. 2019 Sep;86(3):427-435
pubmed: 31199530
Anal Bioanal Chem. 2015 Jul;407(17):4995-5007
pubmed: 25893801
Annu Rev Anal Chem (Palo Alto Calif). 2015;8:61-80
pubmed: 26161972
Curr Alzheimer Res. 2016;13(6):641-53
pubmed: 26825096
PLoS One. 2016 May 19;11(5):e0155694
pubmed: 27196316
Arch Neurol. 2010 Jun;67(6):699-706
pubmed: 20385883
Alzheimers Dement. 2019 Feb;15(2):232-244
pubmed: 30337152
J Pharm Biomed Anal. 2020 Jan 30;178:112812
pubmed: 31639596
Adv Exp Med Biol. 2017;965:3-17
pubmed: 28132174
Alzheimers Dement. 2016 Jul;12(7):815-22
pubmed: 26806385
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 1;1091:53-66
pubmed: 29852382
Anal Chem. 2018 Jan 2;90(1):240-265
pubmed: 29155564
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2042-2052
pubmed: 28664464
J Alzheimers Dis. 2018;65(4):1401-1416
pubmed: 30175979
J Clin Psychiatry. 2006 Nov;67(11):1782-3
pubmed: 17196060
Dement Geriatr Cogn Dis Extra. 2017 May 4;7(1):143-159
pubmed: 28626469
Nat Rev Neurol. 2018 Nov;14(11):639-652
pubmed: 30297701
Anal Chim Acta. 2019 Jul 11;1061:28-41
pubmed: 30926037
Sci Rep. 2016 Mar 09;6:22769
pubmed: 26957294
Clin Biochem. 2010 Aug;43(12):992-7
pubmed: 20457143
J Lipid Res. 2003 Jun;44(6):1071-9
pubmed: 12671038
Metabolites. 2020 Jan 29;10(2):
pubmed: 32013105
Open Biol. 2020 Jun;10(6):200084
pubmed: 32543351
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13139-44
pubmed: 18728191
J Proteomics. 2014 Jun 2;104:37-47
pubmed: 24473279
Crit Rev Clin Lab Sci. 2021 May;58(3):167-179
pubmed: 33137264
Anal Chim Acta. 2019 Sep 3;1069:89-97
pubmed: 31084745
Nat Methods. 2017 Apr 27;14(5):461-462
pubmed: 28448069
Sci Rep. 2013;3:2364
pubmed: 23917584
Front Mol Neurosci. 2017 Mar 15;10:59
pubmed: 28360834
Front Cell Neurosci. 2015 Apr 07;9:109
pubmed: 25904844
Cell. 2012 Mar 16;148(6):1204-22
pubmed: 22424230
Front Neurol. 2018 Jan 12;8:719
pubmed: 29375465
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:154-8
pubmed: 22985726
Alzheimers Dement (Amst). 2015 Sep 2;1(3):295-302
pubmed: 26744734
Neuron. 2014 Nov 5;84(3):608-22
pubmed: 25442939
Metabolomics. 2013 Apr;9(2):280-299
pubmed: 23543913
Mol Nutr Food Res. 2020 Nov;64(22):e2000615
pubmed: 32997396
J Neurosci. 2006 Oct 4;26(40):10129-40
pubmed: 17021169
Metallomics. 2017 Aug 16;9(8):1001-1013
pubmed: 28758652
Ageing Res Rev. 2019 Jul;52:120-128
pubmed: 31039414
J Neurosci. 2017 Jul 19;37(29):6915-6925
pubmed: 28626014
Am J Clin Nutr. 2020 Aug 1;112(2):343-353
pubmed: 32320019
Annu Rev Anal Chem (Palo Alto Calif). 2008;1:579-99
pubmed: 20636090
Metabolomics. 2014 Apr 4;10(2):312-323
pubmed: 25411574
Anal Chim Acta. 2015 Oct 22;898:73-84
pubmed: 26526912
Alzheimers Dement. 2017 Dec;13(12):1327-1336
pubmed: 28602601
Curr Opin Psychiatry. 2020 Jul;33(4):432-438
pubmed: 32149739
Cancer Biol Med. 2020 Feb 15;17(1):181-198
pubmed: 32296585
PLoS One. 2013 May 20;8(5):e63644
pubmed: 23700429
Plant Mol Biol. 2002 Jan;48(1-2):155-71
pubmed: 11860207
Anal Chem. 2009 Nov 15;81(22):9343-52
pubmed: 19839594
BBA Clin. 2015 Nov 14;5:25-8
pubmed: 27051586
Cell Mol Life Sci. 2008 Oct;65(19):3040-8
pubmed: 18560755
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Aug 15;871(2):236-42
pubmed: 18502704
Genet Med. 2016 May;18(5):421-30
pubmed: 26312828
Rapid Commun Mass Spectrom. 2013 Feb 15;27(3):401-8
pubmed: 23280971
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11358-63
pubmed: 19549834
Neurobiol Aging. 2014 Sep;35(9):1992-2003
pubmed: 24746363
Sci Data. 2017 Oct 17;4:170140
pubmed: 29039849
PLoS One. 2012;7(2):e31501
pubmed: 22359596
J Chromatogr A. 2010 Jun 18;1217(25):4087-99
pubmed: 20307888
Bioanalysis. 2016 Jul;8(14):1509-32
pubmed: 27323646
Prog Neurobiol. 2001 Aug;64(6):575-611
pubmed: 11311463
Anal Chem. 2012 Oct 16;84(20):8532-40
pubmed: 22967182
J Proteome Res. 2014 May 2;13(5):2649-58
pubmed: 24694177
Sci Rep. 2020 Mar 2;10(1):3825
pubmed: 32123207
Biochim Biophys Acta Biomembr. 2017 Sep;1859(9 Pt B):1604-1614
pubmed: 28527668
Acta Neuropathol. 2016 May;131(5):645-58
pubmed: 26711459
BMC Med. 2014 Nov 11;12:206
pubmed: 25385447
J Proteome Res. 2016 Feb 5;15(2):608-18
pubmed: 26717242
Transl Psychiatry. 2011 Dec 13;1:e57
pubmed: 22832349
Int J Mol Sci. 2020 Jun 22;21(12):
pubmed: 32580508
Neurology. 2020 Jul 14;95(2):e166-e178
pubmed: 32580974
J Am Soc Mass Spectrom. 2020 Dec 2;31(12):2437-2442
pubmed: 32841564
Methods Mol Biol. 2018;1750:255-269
pubmed: 29512078
Arch Gerontol Geriatr. 2010 Mar-Apr;50(2):171-4
pubmed: 19375179
Mass Spectrom Rev. 2007 Jul-Aug;26(4):606-43
pubmed: 17471576
J Proteome Res. 2020 May 1;19(5):2080-2091
pubmed: 32216312
Curr Protoc Bioinformatics. 2019 Dec;68(1):e86
pubmed: 31756036